Clinical Trial Update: Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating a triple combination of docetaxel, ramucirumab, and pembrolizumab for metastatic or recurrent non-small cell lung cancer …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Stage Iva Non-small Cell Lung Cancer
• Stage Ivb Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Pembrolizumab (pembrolizumab)
• Ramucirumab (ramucirumab)

Snippet

Sponsor: Emory University | Conditions: Metastatic Non-Small Lung Cell Cancer, Recurrent Non-Small Lung Cell Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING